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 Plasmodium falciparum circumsporozoite protein (PfCSP) is the main target antigen in 
development of pre-erythrocytic malaria vaccines. To evaluate PfCSP vaccines in animal 
models, challenge by intravenous sporozoite injection is preferentially used. However, in 
clinical trials, vaccinated human volunteers are exposed to the bites of malaria-infected 
mosquitoes. In this study, we down-selected Escherichia coli-produced full-length PfCSP 
(PfCSP-F), and its three truncated PfCSPs based on their abilities to elicit immune response 
and protection in mice against two challenge models. We showed that immunization with three-
dose of PfCSP-F elicited high PfCSP-specific antibody titers and 100% protection against the 
bites of infected mosquitoes. Meanwhile, three-dose truncated PfCSP induced 60%–70% 
protection after immunization with each truncated PfCSP. Heterologous prime-boost 
immunization regimen with adenovirus–PfCSP–F and R32LR greatly induced complete 
protection against intravenous sporozoite injection. These results suggest that the complete 
elimination of sporozoites in the skin injected by the bites of infected mosquitoes requires 
humoral responses against each region induced by PfCSP-F, whereas induction of fast-acting 
humoral responses to repeat region plays an important role against intravenous sporozoite 
injection when adenovirus-PfCSP-F was used as a priming vaccine. Thus, the protective 
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AdHu5  human adenovirus type 5 
AdHu5-PfCSP   recombinant AdHu5 expressing PfCSP 
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ELISA   enzyme-linked immunosorbent assay 
GAPDH  glyceraldehyde-3-phosphate dehydrogenase 
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i.m.  intramuscular 
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PfCSP-C  PfCSP C-terminus 
PfCSP-Tc/Pb  transgenic P. berghei ANKA parasite line expressed PfCSP under the 
control of the P. berghei CSP promoter 
pfu   plaque-forming unit 
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 v 







Malaria remains a major cause for morbidity and mortality worldwide, predominantly in 
infants and young children in sub-Saharan Africa. It was reported that 216 million cases and 
445,000 deaths due to malaria had occurred in 2016, mainly in children under five years age 
(1). To this end, anti-malarial drugs play the main role in the elimination of erythrocytic stages 
of malaria parasites. However, drug resistance has already developed to all the antimalarial 
drug classes with one notable exception, the artemisinin (2). Therefore, an effective pre-
erythrocytic malaria vaccine is urgently required. The P. falciparum circumsporozoite protein 
(PfCSP) is one of the most intensively studied proteins as a vaccine candidate because it is 
abundant on the surfaces of Plasmodium sporozoites and is highly immunogenic (3). PfCSP 
mainly consists of three regions: The N-terminus comprising region-I, an immunodominant 
central repeat region containing ~40 NANP motifs and up to 4 NVDP motifs, and the C-
terminus comprising region-II (4). 
RTS,S/AS01, a leading malaria vaccine, consists of 19 NANP repeats and the C-terminus 
of PfCSP fused to the hepatitis B surface antigen (5). It has been demonstrated that RTS,S is 
safe and immunogenic in both controlled human malaria infection (CHMI) and field studies (6, 
7). However, it shows low protective efficacy and insufficient long-term protection. Phase 
IIa/IIb clinical trials conducted in Africa revealed that the RTS,S vaccine had partial protection 
in adults (8), children (9, 10), and infants (11, 12). The phase III clinical trials in seven African 
countries confirmed that 51% and 33% protection against clinical malaria was achieved 12 
months after vaccination in children and infants, respectively (13, 14). Though the mechanism 
of RTS,S/AS01 induced protective immune response has not been clarified in details, the CSP-
specific antibodies and CD4+ T-cell responses induced by vaccination have been correlated 
with protection (15). It has been reported that high-titer antibodies against NANP repeats were 
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associated with clinical protections following vaccination with RTS,S/AS01(16). However, 
early studies showed that a NANP repeat-based peptide-in-adjuvant vaccine failed to induce 
protective efficacy in field studies (17, 18). Recently, Tan, et al. revealed that IgG monoclonal 
antibodies (mAb) induced by repeated injection of Sanaria PfSPZ vaccine to Tanzanian 
volunteers bound not only to the repeat region but also PfCSP N-terminal junction (19). I, 
Kisalu et al. reported that a human mAb, which recognizes a unique ‘junctional’ epitope 
positioned between the N-terminus and the central repeat region of PfCSP, provide sterile 
protection against the bites of infected mosquitoes in a rodent malaria model. They suggested 
that mAb can inhibit not only sporozoite motility in the skin but also invasion into hepatocytes 
through interfering with cleavage of PfCSP (20). Moreover, Chaudhury et al. showed that 
phagocytic activities had been correlated with full-length CSP and C-terminus specific Ab titer 
from serum of RTS,S/AS01 recipients (21). These data emphasize the need to induce more 
durable antibody (Ab) with higher potency against NANP repeats and the N- and C-terminus 
of PfCSP. However, only a few studies of the protective immune responses induced by each 
region of PfCSP have so far been conducted (22, 23). Thus, identification of the effective 
region induced by PfCSP-based vaccination would provide better insights in designing novel 
vaccines. Malaria infection is known to be at least partially controlled by humoral (24) and 
cellular immune response (25). The previous researcher in our lab has revealed that PfCSP full-
length (PfCSP-F) in Imject® Alum (Thermo Scientific, Waltham, MA., USA) not only 
conferred complete protection against challenge by the bites of infected mosquitoes but also 
induced both Th2-type immune response (IgG1) and Th1-type immune response (IgG2a and 
IgG2b) (26). Therefore, I used Imject® Alum as an adjuvant in this thesis. 
For evaluation of CSP-based malaria vaccines in animal models, challenge by intravenous 
(i.v.) sporozoite injection has been preferentially used in a range of institutes because the 
sporozoite dose can be predetermined, though it is not the natural mode of infection and it does 
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not involve sporozoite traverse through the skin. The number of i.v. sporozoite injection 
required to infect  naive mice ranges from 30 to 5,000 sporozoites, which is far larger an amount 
than 25 to 250 sporozoites estimated to be inoculated during the bites of infected mosquitoes 
(27). In contrast, in clinical trials, vaccinated volunteers are exposed to bites of malaria-infected 
mosquitoes and expected to protect against infection. It has been reported that P. berghei 
sporozoites are more infectious when delivered by the bites of infected mosquitoes than by i.v. 
sporozoite injection in CD-1 mice passively immunized with mAbs specific to P. berghei CSP 
(28). In the model of controlled human infection, i.v. injection of 3,200 P. falciparum 
sporozoites is needed to achieve 100% infection of malaria naïve volunteers, which is 
equivalent to five infected mosquito bites (29, 30). Ideally, both routes of sporozoite challenge 
should be used to evaluate vaccine efficacy in an animal model before a clinical trial. 
Here, I down-selected PfCSP-in-adjuvant vaccines by comparing the protective efficacy 
in mice using two different challenge models. My results demonstrated that PfCSP-F in Imject® 
Alum induced high Ab responses and elicited perfect protection against the bites of infected 
mosquitoes, and the truncated PfCSPs in ImjectÒ Alum conferred considerably high protection. 
These results suggest that humoral responses to each region of PfCSP are required in 
eliminating skin-stage parasites injected by the bites of infected mosquitoes, resulting in the 
perfect protection by the full-length CSP. Moreover, the adenovirus-prime and repeat region-
boost adjuvanted in ImjectÒ Alum greatly improved the protective efficacy against i.v. 
sporozoite injection, suggesting that induction of fast-acting humoral responses to the repeat 
region is required for the complete protection when challenged by i.v. sporozoite injection.  
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AIMS OF THE STUDY 
 
 PfCSP plays a fundamental role in parasite development as well as the infection and is 
a molecular target of protective antibodies. However, the mechanism of PfCSP induced 
protective immune response has not been clarified in details. Therefore, it is necessary to 
identify the effective region induced by PfCSP-based vaccination. 
The overall aim of this thesis was to down-select Plasmodium falciparum 
circumsporozoite protein (PfCSP)-in-adjuvant vaccines formulation by comparing their 
protective efficacy in mice using two different challenge models. Concurrently, we assessed 
whether the immune responses induced by truncated PfCSP vaccines are as important as those 




MATERIALS AND METHODS 
 
Ethics statement 
All animal care and handling procedures were approved by the Animal Care and Ethical 
Review Committee of Kanazawa University (no. 22118–1) and Jichi Medical University (no. 
09193), Japan. For the animal experiments, all efforts were made to minimize the suffering of 
the animals. Mice were anesthetized with ketamine (100 mg/kg, intramuscular) and xylazine 
(10 mg/kg, intramuscular) when necessary.  
 
Animals and mosquitoes  
Female inbred BALB/c (H-2d) mice were obtained from Japan SLC (Hamamatsu, 
Shizuoka, Japan) and used in all experiments. Mice were housed under pathogen-free 
conditions in Laboratory of Vaccinology & Applied Immunology, Kanazawa University.  
The Anopheles stephensi mosquitoes strain SDA500 was maintained at 27 °C and 50–
70% relative humidity under 12 h-light/12 h-dark conditions. Adults mosquitoes were fed on 
filter paper soaked with a mixture of 5% D(-) fructose and 0.05% p-aminobenzoic acid (Nacalai 
tesque, Inc, Kyoto, Japan) solution. For the production of eggs, mosquitoes were blood fed on 
naïve anesthetized ddY mice. Eggs were collected using water-soaked filter paper on the cup. 
Egg-laying larvae were fed with liquifry (Intrepet, Surrey, England) and larvae were fed on 
tropical fish food (Kyorin, Himeji, Japan). 
 
Vaccine construction and protein purification 
The gene sequences of PfCSP full-length (pfcsp-f) excised from pENTR-D-PfCSP2-G2-
sWPRE (31) were modified from 3D7-strain pfcsp gene with lack of the signal peptide and 
glycosylphosphatidylinositol signal sequence. The pfcsp-f gene was inserted into a modified 
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pET32-b vector that contained thioredoxin-tag (Trx) and hexahistidine-tag (His) at 3’- and 5’-
ends (32). The pfcsp-n (amino acids 19-107 of PfCSP) and pfcsp-c (amino acids 275-377 of 
PfCSP) genes were amplified from pENTR-D-PfCSP2-G2-sWPRE using the primer set shown 
in Table 1. PCR products of N-terminus and C-terminus of PfCSP (termed as PfCSP-N and 
PfCSP-C) were cloned into pENTRTM/D-TOPO® Cloning Kit (Invitrogen, San Diego, USA) 
and retransferred into the EcoRI/XmaI sites of the pET32-b vector. The synthesized r32lr 
cDNA encoding NVDP-(NANP)16-LR-(NANP)16-NVDP (GenScript, Piscataway NJ, USA) 
was inserted into EcoRI/XhoI sites of the pET32-b. 
 
Table 1. Primer set of PCR product for the N- and C-terminus of pfcsp gene 
Encode Primer 
name 
Oligonucleotide primer sequence (5’-3’) 
N-terminus PfCSP-F1 CACCGAATTCCTGTTTCAGGAATACCAGTGCTATGGTa 
PfCSP-R1  CCCGGGTAGGATCAGGATTACCATCGGCAGGb 
 
C-terminus PfCSP-F5  CACCGAATTCAAGAATAATCAGGGAAATGGCCAGa 
PfCSP-R5 CCCGGGCCTGCAGGACGGAGCTGCACTTCTCCATCT 
TACAAATTTTCTTTTCAATATCb 
a Underlining indicated a newly EcoRI site created  
b Underlining indicated a newly XmaI site created 
 
All recombinant proteins were produced in Escherichia coli using 1 mM IPTG as protein 
expression inducer. The cell pellets of PfCSP-F, -R32LR and -C were lysed with CelLytic® B 
cell lysis as soluble forms and protein purification were conducted using Ni-NTA Superflow 
followed by Hiprep® Q HP 16/10 anion chromatography column (GE Healthcare, Uppsala, 
Sweden). The PfCSP-N pellet was lysed with 6 M Guanidine-HCl as an inclusion body and 
purified under an in-column refolding method as described previously (33, 34). The purity of 
the protein was carried out by sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE). The recombinant protein yield and residual endotoxin contaminations were 
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measured by PierceTM BCA Protein Assay Kit (Thermo Scientific, Meridian Rd., USA) and 
PierceTM LAL Chromogenic Endotoxin Quantitation Kit (Thermo Scientific), respectively. 
 
Preparation of infected mosquitoes  
Transgenic P. berghei parasites expressing the full-length pfcsp gene of the strain 3D7 
parasite (PfCSP-Tc/Pb) were used in my studies. These transgenic parasites were generated by 
replacing the pbcsp gene with pfcsp gene as described previously (35). 
Preparation of mosquitoes infected with PfCSP-Tc/Pb parasites (35) was conducted at 
the Kanazawa University, Japan according to the standard protocol (34, 36). Frozen stock of 
red blood cell (RBC) infected with PfCSP-Tc/Pb parasite was intraperitoneally injected into 
ddY mice (termed P1 mice) in different volumes. Parasitemia was monitored up to 15% and 
then cardiopuncture blood was transferred from P1 to other ddY mice (termed P2 mice) 
following intraperitoneally injected by phenylhydrazine hydrochloride three days before blood 
transfer. Three days after blood transfer, 7-14 days old mosquitoes were blood fed for 15-30 
minutes on P2 mice (Figure 1). Mosquitoes were maintained at 19–21 °C on a 12-hour day-
night cycle and fed with a fructose/PABA solution for 21 days in a humidified incubator. The 
infection rate was checked at day 11 and 21 after blood feeding for oocyst and sporozoite 
positive in midgut and salivary gland, respectively. 
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Immunization and challenge infection  
Homologous protein immunizations were conducted by three doses at a 3-week interval 
with 10 µg of PfCSP-F, -N, -R32LR or –C protein with either Imject® Alum (Thermo 
Scientific) or AlumVax Hydroxide (OZ Biosciences, Marseille, France). Mice administrated 
with phosphate-buffered saline (PBS) were used as a control. The doses of recombinant 
proteins per mouse were 100 µl of protein plus 100 µl of Imject® Alum for intraperitoneal (i.p.) 
administration and 50 µl of protein plus 50 µl of adjuvant for intramuscular (i.m.) 
administration. For the heterologous prime-boost immunization regimen, mice were i.m. 
immunized with 5 × 107 plaque-forming units of AdHu5–PfCSP–F and i.p. immunized with 
either 10 µg of PfCSP-F, PfCSP-N, R32LR, or PfCSP-C in ImjectÒ Alum at 3-week interval. 
Sera from immunized mice were collected from the tail vein just before challenge for 










Figure 1. Preparation of mosquitoes infected with PfCSP-Tc/Pb parasite. Red blood cell 
infected with PfCSP-Tc/Pb parasite was injected into P1 mouse. Blood infected with PfCSP-
Tc/Pb parasite from P1 mouse was transfer into P2 mouse three days after P2 mice treated with 
phenylhydrazine hydrochloride. Mosquitoes blood feeding was performed three days after 
parasite developed in P2 mice. The mosquitoes infection rate was checked on day 11 and 21 
after blood feeding. 
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To evaluate the vaccine efficacy, at 2-week after the final immunization, mice were 
challenged against either by intravenous sporozoite injection or the bites of Anopheles 
stephensi mosquitoes infected with PfCSP-Tc/Pb. The bites of infected mosquitoes were 
performed by minimum two and a maximum of six bites of the infected mosquitoes for 15 
minutes. After feeding, the salivary glands of all blood-filled mosquitoes were dissected to 
confirm the presence of sporozoites and mosquito feeds were performed repeatedly when 
necessary (Figure 3A).  
The i.v. sporozoite injection was conducted by salivary gland dissection of infected 
mosquitoes. Briefly, salivary glands were collected in RPMI-1640 media (Gibco, Life 
technologies, NY, USA) and homogenized by a plastic homogenizer and the number of 
sporozoites were counted by C-Chip hemocytometer (NanoEnTek, MA, USA). Either 500 or 
















Figure 2. (A-B) Immunization scheme. (A) Mice were immunized either intraperitoneally or 
intramuscularly with protein in adjuvant, with three doses at 3-week intervals. (B) Mice were 
intramuscularly immunized with AdHu5-PfCSP and intraperitoneally immunized with protein 
in Imject® Alum three weeks after the first immunization. (A-B) Two weeks after the final 




The positive P. berghei blood-stage infection was checked with a microscopic 
examination of Giemsa-stained thin smears of their tail blood, prepared on days 5-9, 11, and 
14 after challenge. To confirm the negative for infection, a minimum of 20 fields of the thin 
blood smear (magnification, 1,000 ×) were examined (Figure 4). Protection was defined as the 

















Figure 3. Challenge infection. (A) The bites of mosquitoes infected with PfCSP-Tc/Pb. The 
mouse was challenged by the bites of 2 to 6 mosquitoes infected with PfCSP-Tc/Pb. (B) 
Intravenous sporozoite injection. Mice were challenged by intravenous injection via the tail 




Enzyme-linked immunosorbent assay (ELISA)  
ELISA was performed by pre-coated of 0.4 µg/well of PfCSP-F, -N, R32LR or -C 
proteins on EIA/RIA plate (Corning Inc.; Corning, New York, USA) overnight at 4 oC. 
Unoccupied protein binding sites were blocked for 1 h with 1% bovine serum albumin in PB) 
and followed by incubation of diluted sera from the immunized and control mice. Antigen-
specific IgG was incubated with horseradish peroxidase-conjugated anti-mouse and developed 
with both peroxidase substrate solution including hydrogen peroxide and 2, 2’-azino-bis-(3-
ethylbenzothiazoline-6-sulfonic acid) diammonium salt as described previously (35). The 
endpoint titers were expressed as the reciprocal of the last dilution that gave an optical density 
at 414 nm of 0.15 U above the value of the negative control (< 0.1) as described previously (36, 















Fig. 4. Microscopic examination of Giemsa-stained thin smears Blood. (A–B) 
Confirmation of blood-stage parasitemia on day 14 after challenge in the thin blood smear. 




Indirect immunofluorescent assay (IFA) 
a. Sporozoite  
PfCSP-Tc/Pb sporozoites isolated from mosquitoes salivary glands were loaded onto 
glass slides and fixed with acetone/methanol (1:1) in -20 oC and then blocked with 10% normal 
goat serum. Slides were incubated with the 2-fold serial dilution of sera from immunized mice 
for 1 h, washed with PBST and PBS, incubated with FITC conjugated goat anti-mouse IgG for 
1 h, and then again washed with PBST and PBS. VECTASHIELD® containing 4¢, 6-diamidino-
2-phenylindole was used for nuclei staining. Images were taken by A BZ-X700 fluorescence 
microscope. Endpoint titer was determined as the lowest serum dilution to give sporozoite 
surface fluorescence above negative sera control level. 
 
b. AdHu5-PfCSP 
HEK293T cells were transduced with the Ad vaccines on an 8-well chamber slide at a 
MOI = 10. Cells were fixed with 100% methanol for 30 min at 24 h post-infection. The slides 
were blocked with NGS for 1 h and incubated for 1 h at room temperature with Alexa Fluor 
488-conjugated 2A10 diluted 1:100 in blocking solution. Image was taken by A BZ-X700 
fluorescence microscope. 
 
Transgenic sporozoite neutralization assay  
HepG2 cells were seeded for 24 hours at a density 6 × 104 cells/well in a 48-well cell 
culture plate. The cells were maintained in Dulbecco's Modified Eagle Medium (DMEM) 
complete medium that contained 10% Fetal Bovine Serum, 1% Minimum Essential Medium 
Non-Essential Amino Acids (MEM-NEAA), and 1% penicillin-streptomycin. Sporozoites 
(104) from mosquitoes infected with PfCSP-Tc/Pb parasite were incubated in the presence of 
10 µl (1:5 dilution) of sera for 40 min on ice. Subsequently, controls were prepared with an 
equal number of sporozoites incubated in 10 µl (1:5 dilution) nonimmune sera or 10 µl mAb 
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2A10 (10  µg/ml) specific for the repeats of P. falciparum. Then, sporozoites were added into 
HepG2 cultures and maintained at 37 oC in a 5% CO2 incubator. The incubation was carried 
out for 48 h with the changes of culture media every 24 h (38, 39). After 48 h, the cells were 
washed with PBS, and total RNA isolation was performed by using RNeasy® Plus Mini Kit  
(Qiagen, Hilden, Germany) and the total RNA was reverse-transcribed using TaqManTM 
Reverse Transcription Reagents according to the manufacturers’ instructions. Quantitative 
analysis of RNA transcripts was performed by Real-time PCR with SYBR® Green Premix Ex 
Taq™ (Takara Bio Inc., Kusatsu, Japan) using pPb 18s rRNA and human gapdh primers (Table 
2).  
 
Table 2. Primers used for quantitative analysis of RNA by Real-time PCR 
Encode Primer name Sequences (5’-3’) 
P. berghei 18S 
rRNA 
pPb 18s rRNA-F2 CCAACACTTAGTCGGCATAGTT 
pPb 18s rRNA-R2 GGAGACAAACAACTGCGAAA  
 
GAPDH phGAPDH-F1 TGCCCCCATGTTCGTCATG 
phGAPDH-R1 TGTGGTCATGAGTCCTTCC 
 
The temperature profile of the reaction was 95 °C for 30 s, followed by 40 cycles of 
denaturation at 95 °C for 10 s and annealing/extension at 60 °C for 45s. The copy number of 
18S cDNA molecules was determined by linear regression analysis using the Ct values 
obtained from the infected cells, which was applied to those from plasmid 18S cDNA.  
 
Statistical analysis  
A two-tailed Fisher’s exact probability test was performed to determine statistical 
differences in the protective efficacies of the vaccines using SPSS software (version 19, 
Chicago, IL, USA). In all other experiments, statistical differences between the experimental 
groups were analyzed by the methods described in the individual figure legends and the 
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significance level used was (α) = 0.05. Statistical analyses were performed with either Prism 




Purification of PfCSP-F and truncated proteins. 
Construction of PfCSP protein from native 3D7 strain consists of signal peptide, PfCSP19-
377, and glycosylphosphatidylinositol anchor sequence (Figure 5A). PfCSP-F protein consists 
of PfCSP19-377, lack of the signal peptide and glycosylphosphatidylinositol signal sequence 
(Figure 5B). PfCSP-N and -C consist of PfCSP19-107 and PfCSP275-377, respectively (Figure 5C 
and 5E). R32LR consists of NVDP-(NANP)16-LR-(NANP)16-NVDP (40, 41) (Figure 5D).  In 
this thesis, all of recombinant PfCSPs protein was combined with the thioredoxin (Trx)-tag and 
hexahistidine (His)-tag. Trx-tag, molecular weight of approximately 12 kDa, was used to 
increase the solubility and thermal stability of proteins (42). His-tag was used to facilitate the 




PfCSP-F and three kinds of truncated proteins with Trx- and His-tags were produced in E. 
coli expression system. These E. coli-produced proteins were purified and analyzed by SDS-
PAGE (Figure 6). The band sizes of PfCSP-F (70 kDa), -N (35 kDa), R32LR (45 kDa) and -C 
(37 kDa) were slightly bigger than the predicted molecular weights (60, 31, 34 and 33 kDa, 
respectively). It might be due to a large number of polar residues asparagine in PfCSP-F and 
R32LR sequences (44, 45) and also His-tags at the N- and C-terminus of all sequences (Figure 




















Figure -. Construction of recombinant PfCSPs vaccines. (A) Schematic diagram of 
PfCSP protein. Native P. falciparum CSP from strain 3D7, consisting of a signal peptide 
and glycosylphosphatidylinositol signal sequence, N-terminal region, central NANP 
repeats, and C-terminal region, is shown as PfCSP (3D7 strain). (B-E) Vaccine 
construction: PfCSP-F (Leu19–Val377), PfCSP-N (Leu19–Asn107), R32LR (NVDP–
[NANP]16–LR–[NANP]16–NVDP), and PfCSP-C (Asn275–Val377) proteins were 
fused with a thioredoxin tag and hexahistidine tag. Signal peptide, 
glycosylphosphatidylinositol, hexahistidine tag, and thioredoxin tag are shown as SP, 

















Figure 5. Construction of recombinant PfCSPs vaccines. (A) Schematic diagram of PfCSP 
protein. Native P. falciparum CSP from strain 3D7, consisting of a signal peptide and 
glycosylphosphatidylinositol signal sequence, N-terminal region, central NANP repeats, 
and C-terminal region, is shown as PfCSP (3D7 strain). (B-E) Vaccine construction: 
PfCSP-F (Leu19–Val377), PfCSP-N (Leu19–Asn107), R32LR (NVDP–[NANP]16–LR–
[NANP]16–NVDP), and PfCSP-C (Asn275–Val377) proteins were fused with a 
thioredoxin tag and hexahistidine tag. Signal peptide, glycosylphosphatidylinositol, 




Comparison of protective efficacy and Abs induction between PfCSP-F and its 
truncated protein against the bites of infected mosquitoes 
Table 3 summarizes the protective efficacy results for PfCSP-F and its truncated region 
proteins against the bites of infected mosquitoes. First, mice were intraperitoneally immunized 
with three-dose of indicated vaccine in ImjectÒ Alum at 3-weeks interval. At two weeks after 
final immunization, mice were challenged by the bites of 2 to 6 mosquitoes infected with 
PfCSP-Tc/Pb parasite. All mice immunized with PfCSP-F protein in ImjectÒ Alum were 
completely protected while PfCSP-N, R32LR and -C conferred considerably high protection 
by 60%, 70%, and 69%, respectively (Table 3). It indicates that full-length of PfCSP is required 













Figure 6. expression of recombinant PfCSP vaccines. (A) SDS-PAGE of purified proteins 
PfCSP-F (70 kDa), -N (35 kDa), R32LR (45 kDa), and -C (37 kDa). Marker, PfCSP-F, -N, 




Table 3. The protective efficacies of PfCSP-F and its truncated region proteins against the 
bites of infected mosquitoesa 
Vaccine Mean No. infected mosquitoes  ± S.D. per mouse 
No. protected mice/total 
(%)b 
PBS 3.1 ± 1.1 0/19 (N/A)c 
PfCSP-F 3.1 ± 1.1 16/16 (100)c,d 
PfCSP-N 3.3 ± 1.2 6/10 (60)d 
R32LR 3.1 ± 1.0 7/10 (70)d 
PfCSP-C 3.1 ± 0.7 11/16 (69)c,d 
aMice were intraperitoneally immunized with three-dose of indicated vaccine in ImjectÒ 
Alum at 3-weeks interval. At two weeks after final immunization, mice were challenged by 
the bites of 2 to 6 mosquitoes infected with PfCSP-Tc/Pb sporozoites 
bMice were checked for blood-stage infections by microscopic examination of Giemsa-stained 
thin smears of tail blood after challenge infections. Protection was defined as the complete 
absence of blood-stage parasitemia on day 14 post-challenge. 
cCumulative data from two independent experiments. 
dEach group of immunized mice was compared with the PBS group to test for statistically 
significant differences using Fisher’s exact probability test. p < 0.0001. 
 
Next, I investigated the Ab titer induced by PfCSP-F and its truncated PfCSP 
immunization. The mice sera were collected just before challenge infection. The highest anti-
PfCSP Ab titer was induced when PfCSP-F was administered (Figure 7A). PfCSP-C and 
R32LR induced significantly higher anti-PfCSP Ab titers than did PfCSP-N (Figure 7A). As 
PfCSP-F provided full sterile protection, we next examined the PfCSP-region-specific Ab titer 
in mice immunized with PfCSP-F. PfCSP-F immunization induced high titers of anti-PfCSP-
C and anti-PfCSP-N Abs, whereas the anti-R32LR Ab titer was moderate (Figure 7B). This 






To investigate the reactivity of immune sera with sporozoites, I performed IFA assay. First, 
mice were intraperitoneally immunized with three-dose of PfCSP-F and its truncated region 
protein in ImjectÒ Alum at 3-weeks interval. Next, individual serum samples were collected 
from cardiac at two weeks after the final immunization. An IFA was performed using 
sporozoites dissected from mosquito’s salivary glands. As expected, the immune sera of the 
PfCSPs-immunized mice reacted strongly with the sporozoites (Figure 8A) and the pattern of 



















Figure 7. IgG Ab responses induced by PfCSP-F and truncated proteins in ImjectÒ Alum. 
(A–B) Mice were immunized intraperitoneally with the indicated protein in Imject® Alum, 
with three-dose at 3-week interval. Two weeks after the final immunization, individual serum 
samples were collected. (A) Anti-PfCSP IgG Ab titers of the indicated immune sera were 
measured with an ELISA. (B) Sera from the mice immunized with PfCSP-F in (A) were 
examined for IgG Ab responses against PfCSP-N, R32LR, and PfCSP-C with ELISA. PfCSP-
F, PfCSP-N, and PfCSP-C proteins are shown as F, N, and C, respectively. Bars and error bars 
indicate means and SD, respectively. Bars and circles indicate geometric means and individual 
values, respectively. p values were determined with the Kruskal–Wallis test with Dunn’s 




Antibodies can block infection in several ways, including neutralizing the sporozoites to 
prevent the binding to its target, opsonizing the sporozoites to destroy through phagocytosis 
and antibody-dependent cellular cytotoxicity, and activating the complement system (46). 
Therefore, I further evaluated the neutralizing activity of immune sera from mice immunized 
with PfCSPs using an in vitro sporozoites neutralizing assay. All immune sera significantly 
reduced rRNA parasite in HepG2 cell compared with the nonimmune sera group (Figure 8). 
The mean parasite 18s rRNA levels of PfCSP-Tc/Pb in the sera of mice immunized with 





















Figure 8. Reactivity of immune sera with sporozoites. (A–B) Mice were immunized 
intraperitoneally with the indicated protein in Imject® Alum, with three-dose at 3-week 
interval. Two weeks after the final immunization, individual serum samples were collected. 
(A) Immunofluorescence assay of PfCSP-Tc/Pb sporozoites incubated with indicated immune 
sera. Bar = 10 µm. (B) Anti-PfCSP IFA titers of indicated immune sera were measured with 
immunofluorescence assay. Bars and error bars indicate means and SD, respectively. 
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45% (38,338 copies), 15% (12,567 copies), or 29% (25,177 copies), respectively, compared 
with those in the nonimmune sera (85,733 copies) (Figure 8). This result showed that anti-
repeat sera act as the most powerful neutralizing Abs among other truncated regions sera. 
Collectively, immunization with PfCSP-F could confer strong IgG responses in both quality 
and quantity, which were consistent with its sterile protective efficacy. 
 
 
Comparison of challenge routes for the evaluation of PfCSP-F vaccines  
To investigate the influence of the challenge route on PfCSP-F vaccine, mice immunized 



















Figure 9. Sporozoite neutralization assay. PfCSP-Tc/Pb sporozoites were incubated with the 
indicated sera before their addition to HepG2 cells. The copy numbers of P. berghei 18s rRNA 
were determined with quantitative reverse transcription–PCR 48 h after sporozoite incubation 
with HepG2 cells. Nonimmune sera (NIS) and 2A10 mAb were used as the controls. Sera from 
mice immunized with PfCSP-F, PfCSP-N, and PfCSP-C are shown as F, N, and C, 
respectively. Bars and error bars indicate the mean numbers and standard deviations of PfCSP 
18s rRNA copies (1:1000). p values were determined with ANOVA and Tukey’s correction. 
*p < 0.05; **p < 0.01; and ***p < 0.001. 
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compared with Alhydrogel (AlumVax Hydroxide), which is a licensed adjuvant for human. 
Since licensed human vaccines in alum are inoculated intramuscularly, PfCSP-F either in 
ImjectÒ Alum or AlumVax Hydroxide adjuvant were i.m. immunized. The i.m. immunization 
of PfCSP in Imject® Alum induced Ab titers as high as i.p. immunization (Figure 7A and 10). 
This result shows that the alteration of immunization route has no effect on Ab titer induction. 
However, when the challenge route was changed into i.v. sporozoite injection, the protective 
efficacy was declined into 50% (Table 3 and 4). This result indicate that the protective efficacy 
of CSP-based vaccines appears to be highly dependent on the challenge route.  
 
Table 4. Comparison of adjuvant effect on ImjectÒ Alum with AlumVax hydroxide against 
intravenous sporozoite injectiona 
 
aMice were intramuscularly immunized with three-dose of PfCSP-F in indicated adjuvant at 3-
week interval. At two weeks after final immunization, mice were challenged by intravenous 
injection of 1,000 PfCSP-Tc/Pb sporozoites.  
bProtection are defined as described in Table 3. 
cProtective efficacy was calculated by using the formula: % protective efficacy = [1– [(number 
of infected mice in the vaccine group/total number of mice in the vaccine group)/(number of 
infected mice in the non-immunized group/total number of mice in the non-immunized group)]] 
x 100. N/A, not applicable. 
 
 
Recent study demonstrated that Ab titers elicited by i.p. immunization of hapten-carrier 
antigen in Alhydrogel significantly induced higher than that induced by Imject® alum (47). 
However, in my study, Ab titer induced by AlumVax Hydroxide (Alhydrogel) was higher than 
Vaccine Adjuvant No. protected mice/total 
(% protective efficacy)b,c 
PBS - 2/10 (N/A) 
PfCSP-F Imject® Alum 6/10 (50) 
PfCSP-F AlumVax hydroxide 3/8 (21.9) 
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that ImjectÒ Alum but there was no significant difference (Figure 10). Though PfCSP in 
Imject® Alum induced the Ab titers as high as that in AlumVax Hydroxide, the protection 
elicited by PfCSP in Imject® Alum is still better than AlumVax Hydroxide. These results 
suggest that the protection conferred by immunization in Imject® Alum might be influenced 




In this study, we showed that the challenge route influences the protective efficacy. 
Therefore, to elicit higher protection against challenge by i.v. sporozoite injection as well as 




















Figure 10. IgG Ab responses induced by PfCSP-F in ImjectÒ Alum and AlumVax Hydroxide. 
Mice were immunized intramuscularly with PfCSP-F in the indicated adjuvant, with three-
dose at 3-week interval. Two weeks after the final immunization, individual serum samples 
were collected. Bars and error bars indicate the mean numbers and standard deviations, 
respectively. p values were determined with the Student’s t-test 
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responses by altering type of adjuvant and/or viral vector is required. 
 
Heterologous AdHu5-PfCSP-prime/R32LR-boost conferred complete protection 
against intravenous sporozoite injection 
Despite the enhancement both humoral and cellular immune responses, the cost-
effectiveness are important to be considered for clinical use. Although the three doses 
immunization with PfCSP-F protein in ImjectÒ Alum resulted in high protective efficacy 
against the bites of infected mosquitoes, a two-dose malaria vaccine would be much desirable 
in malaria-endemic country. Recently, our group have shown that a two-dose heterologous 
prime-boost immunization regimen using adenovirus and baculovirus vectors harboring the 
full-length PfCSP (pfcsp-f) gene conferred sterile protection against sporozoite challenge both 
by mosquito bites and i.v. sporozoite injection (48). To apply the current finding, I tested a 
two-dose heterologous adenovirus-prime/protein-boost immunization regimen.  
To examine of PfCSP in mammalian cells HEK293A cells, I fixed cells infected with 
AdHu5-PfCSP (MOI = 10) and incubated with an anti-PfCSP mAb 2A10 conjugated with 
Alexa Fluor 488. As expected, strong immunofluorescent signals were detected on the surfaces 
of infected cell, indicating that VSV-G was anchored to the cell membranes (Figure 11). 
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Table 5 summarizes the protective efficacy results for AdHu5–PfCSP–F-prime and 
protein-boost against challenge by i.v. sporozoite injection. AdHu5–PfCSP–F-prime/R32LR-
boost immunization conferred complete protection (100%), whereas booster with other 
truncated region, PfCSP-N or PfCSP-C conferred partial protection (44%, and 56%, 























Figure 11.  Expression of PfCSP in mammalian cells HEK293A cells (3 × 104) were infected 
with AdHu5-PfCSP. HEK293A cells were transduced with AdHu5-PfCSP (MOI = 10). After 
24 h, the cells were fixed with 100% methanol for 30 min, and incubated with Alexa Fluor 
488-conjugated 2A10. Cell nuclei were visualized with 4′ ,6-diamidino-2-phenylindole 
(DAPI; blue). Bars = 50 μm. 
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Table 5. The protective efficacies of the AdHu5-PfCSP-prime/protein-boost regimen against 
intravenous sporozoite injectiona 
Vaccine Boost No. protected mice/total (% protective efficacy)b  
PBS - 1/10 (N/A) 
AdHu5-PfCSP PfCSP-F 5/10 (44) 
AdHu5-PfCSP PfCSP-N 5/10 (44) 
AdHu5-PfCSP R32LR 10/10 (100)c 
AdHu5-PfCSP PfCSP-C 6/10 (56)d 
aMice were intramuscularly immunized with AdHu5-PfCSP at day 0, and intraperitoneally 
immunized with indicated protein in Imject® Alum. At two weeks after final immunization, 
mice were challenged by intravenous injection of 500 PfCSP-Tc/Pb sporozoites 
bComplete protection and protective efficacy are defined as described in Table 4. 
c,dEach group of immunized mice was compared with the PBS group to test for statistically 
significant differences using Fisher’s exact probability test. cp < 0.0001; dp < 0.05 
 
 
 Heterologous prime-boost strategies have been shown to increase the magnitude of the 
vaccine-specific immune responses (49). In this study, heterologous AdHu5–PfCSP–F-
prime/PfCSP-F-boost immunization induced the highest anti-PfCSP Ab titer (Figure 12). 
Among truncated PfCSP-boost immunization, AdHu5–PfCSP–F-prime/PfCSP-C-boost and 
AdHu5–PfCSP–F-prime/R32LR-boost immunization induced significantly higher anti-PfCSP 
Ab titers than did PfCSP-N (Figure 12). As AdHu5–PfCSP–F-prime/R32LR-boost 
immunization provided full sterile protection, we next examined the PfCSP-region-specific Ab 
titer. Anti-R32LR Ab titer was induced 1.5 to 2 times higher other region did (Figure 12). 
Surprisingly, mice boosted with PfCSP-F inducing less anti-R32LR Ab titers than did anti-
PfCSP-N failed to confer complete protection against challenge by i.v. sporozoite injection 
(Table 5). This result suggests that induction of humoral responses to the repeat region plays 
an important role against challenge by i.v. sporozoite injection.  
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Ad5 based vaccines were known to elicit potent cellular responses by secreting CSP 
specific CD8+ T cells and IFNγ in mice (50, 51). Therefore, I used Adhu5 to induce strong Th1 
and balanced IgG2/IgG1 responses to protein vaccine antigens. IgG1 titers was predominately 
induced by PfCSP-C-boost, whereas the the highest IgG2a titers were induced by PfCSP-F-
boost. IgG2b titer induced by PfCSP-C was higher than that other booster but there was no 
significant difference (Figure 13A). The IgG2a/IgG1 ratios induced by PfCSP-F, -N, -R32LR, 
and -C boost were 2.73, 1.84, 2.54, and 3.89, respectively (Fig. 13B), indicating that all booster 
















Figure 12. IgG Ab titer induced by AdHu5-PfCSP as a prime and indicated PfCSP protein in 
Imject® Alum as a boost. Mice were i.m. immunized with 5 × 107 plaque-forming units of 
AdHu5–PfCSP–F and i.p. immunized with either 10 µg of PfCSP-F, PfCSP-N, R32LR, or 
PfCSP-C in Imject® Alum at 3-week interval. Two weeks after the final immunization, 
individual serum samples were collected. Anti-PfCSP IgG Ab titers were measured with an 
ELISA. AdHu5–PfCSP–F are shown as AdHu5. Bars and error bars indicate means and SD, 
respectively. p values were determined with two way ANOVA and Tukey's correction. *p < 





Since the i.m. immunization of PfCSP-F in Imject® Alum challenged by i.v. challenge 
reduced the protective efficacy, we hypothesized that the induction of cellular immunity 
induced by AdHu5–PfCSP–F as a prime would increase the protective efficacy. However, in 
my study, AdHu5–PfCSP–F-prime/PfCSP-F-boost immunization did not increase the 
protective efficacy over homologous protein immunization when it was challenged by i.v. 
sporozoite injection. Consistently, Ockenhouse et.al revealed that though Adenovirus-
prime/RTS, S boosts (ARR) induced significantly higher antigen-specific CD4+ T-cells 
compared to homologous RTS, S (RRR), vaccine efficacy of ARR-group remain the same with 
RRR-group. They hypothesized that first, CD4+ T-cells may be active in an anatomical 
compartment other than that detectable in the blood. Second, a threshold level of CD4+ cells 
may need to be reached in order to observe a significant impact on efficacy (1). Overall, 
induction of region-specific humoral immune response might influence in the protective 














Figure 13. PfCSP-specific Abs in mice immunized with AdHu5-PfCSP as a prime and 
indicated PfCSP protein in Imject® Alum as a boost. Anti-PfCSP IgG Ab titers were measured 
with an ELISA. (A) The anti-PfCSP IgG subclasses and (B) the IgG2a/IgG1 ratios were 
calculated. Bars and error bars indicate means and SD, respectively. p values were determined 





Plasmodium falciparum is most lethal malaria parasite. Much effort has been done to 
develop a vaccine against this parasite. PfCSP is the main target of malaria antigen because it 
is present on the surface of sporozoites and has a critical role in motility, attachment, and 
invasion of hepatocytes. To this end, the major target of protective PfCSP Abs is related to the 
repeat region and the role of other Abs against other PfCSP regions is not well understood. 
Therefore, understanding both the protective efficacy and Abs responses related to each region 
would provide better insights in designing novel vaccines. In this study, I focused on 
examination the protective efficacy and Ab responses induced by PfCSPs protein vaccine in 
two different challenge models. Here I demonstrate that three-dose of PfCSP-F in Imject® 
Alum elicited high PfCSP-specific antibody titers and 100% protection against challenge by 
the bites of infected mosquitoes and heterologous prime-boost adenovirus–PfCSP–F/ R32LR 
induced complete protection against challenge by i.v. sporozoite injection. 
 
PfCSP-F immunization is required to obtain complete protection against challenge by 
the bites of infected mosquitoes 
Here, I showed that PfCSP-F in Imject® Alum consistently induced high titers of PfCSP-
specific IgG Abs and complete protection against challenge by the bites of infected mosquitoes. 
All truncated PfCSPs in Imject® Alum conferred high protection (60%–70%), indicating that 
all regions contribute to this protection. This result is consistent with other studies identifying 
protective human mAbs that potently bind to the ‘junctional’ epitope between the N-terminus 
and the central repeat of PfCSP (19). The present study demonstrated that PfCSP-C 
immunization conferred protection and anti-PfCSP-C Abs reacted with the sporozoites. 
Consistently, a synthetic peptide corresponding to the C-terminus of P. berghei CSP has been 
associated with protection in mice (52). However, anti-C-terminus Abs induced by live 
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Plasmodium sporozoite in humans under chloroquine prophylaxis have weak inhibition of 
parasite traversal (53). In fact, CSP attaches to hepatocytes via region-I located in the N-
terminus to invade liver cells (54), whereas the repeat region mediates sporozoite infectivity in 
either the mosquito or mammalian host (55). In addition, sporozoite motility is also affected 
by the disruption of region-II at C-terminus (56). The evidence that Abs induced by three 
regions substantially blocked the sporozoites invasion of HepG2 cells is consistent with the 
highest protective efficacy afforded by PfCSP-F. Thus, the humoral immune responses to each 
region of PfCSP play important roles for protection against challenge by the bites of infected 
mosquitoes. 
 
Protective efficacy of CSP-based vaccines appears to be highly dependent on the 
challenge route 
Flores-Garcia et al. (2018) showed that dermal antisporozoite immune responses are 
important for protection (57). They demonstrated that anti-CSP Abs impaired sporozoite 
motility in the skin and infection of dermal blood compared with naive mice. In contrast, 
immunization with irradiated sporozoites demonstrated that anti-sporozoite Abs had minor 
protective role and could not compensate for IFN-g deficiency against challenge by i.v. 
sporozoite injection (58, 59). An ineffective of anti-sporozoite Abs in those experiments might 
be due to the different challenge route. Challenge by i.v. sporozoite injection is not the natural 
mode of sporozoite infection and does not involve sporozoite traversal through the skin. 
Consequently, the i.v. sporozoite challenge model does not assess the Ab activity induced by 
vaccines in the skin traversal phase. Therefore, the bites of infected mosquitoes are more 
suitable for the evaluation of pre-erythrocytic malaria vaccines because this is the natural mode 
of sporozoites infection. During the bites of infected mosquitoes, the sporozoites migrate 
slowly from the dermal tissue to the bloodstream (60, 61), so there is more opportunity for anti-
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sporozoite Abs to neutralize them and prevent the sporozoites from entering the bloodstream 
(62). In contrast, sporozoites directly enter the bloodstream after i.v. sporozoite injection, so a 
few sporozoites may escape from the anti-CSP Abs and reach the liver. Consistent with this, 
in the present study, we showed that the protective efficacy of PfCSP in Imject® Alum was 
reduced to 50% when mice were challenged by i.v. sporozoite injection compared with 
challenge by the bites of infected mosquitoes. Therefore, the induction of high-affinity Abs 
may be required for the complete elimination of the sporozoites challenged by i.v. injections. 
 
R32LR immunization is required to obtain complete protection against challenge by 
i.v. sporozoite injection 
Recently, the most effective mAbs isolated from a protected Tanzanian volunteer 
immunized with PfSPZ were shown to be associated with the repeat region of CSP (19). In the 
present study, the heterologous AdHu5–PfCSP–F-prime/R32LR-boost immunization regimen 
conferred complete protection against challenge by i.v. sporozoite injection. In my study, 
together with the cellular immune responses induced by AdHu5–PfCSP (48), the humoral 
immune responses induced by R32LR-boost improved the protective efficacy over 
homologous R32LR immunization. Because the anti-repeat Abs were able to neutralize the 
sporozoites directly, without the complement or other cell mediators, they act as the most 
powerful neutralizing Abs among all other regions (63). Consistently, my study revealed that 
anti-repeat Abs has higher neutralization activity than other regions. The superior action of 
anti-repeat Abs may be attributable to their multivalent interactions and higher affinity of the 
repeat region (4, 64). Therefore, the induction of the humoral responses by the repeat-boost is 





In conclusion, we showed that full-length PfCSP with Imject® Alum induced a potent 
humoral immune response to each region of PfCSP and conferred complete protection on mice 
against challenge by the bites of infected mosquitoes. Anti-repeat Abs effectively conferred 
protection against challenge by i.v. sporozoite injection when combined with adenovirus–
PfCSP-F in a malaria vaccine. Therefore, the mechanism of the protection by CSP-based 
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